Testing for germlineBRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identifiedBRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with breast cancer. Emerging breast and ovarian cancer ...
Several barriers to genetic testing exist, including limited access to testing facilities, trained counselors, and psychosocial support, as well as the financial burden of testing. Here, we describe current implications of gBRCAm testing for patients with breast cancer, summarize current approaches to ...
First, a brief risk assessment test. For those determined to be at risk, next would be genetic counseling. Finally, for women assessed to have the most risk after the first two steps, testing for the BRCA gene mutations. The task force recommended against testing for the BRCA mutations in ...
1. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. 2. Robson M, et al. Olaparib...
The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol. 2010;7:708–17.Alison H. Trainer, Craig R. Lewis, Kathy Tucker, Bettina Meiser, Michael Friedlander, Robyn L. Ward. (2010) The role of BRCA mutation testing in determining breast cancer therapy. ...
[1]Armstrong K, Weiner J, Weber B, Asch DA. Early adoption of BRCA1/2 testing: who and why. Genet Med. 2003;5(2):92-98. doi:10.1097/01.GIM.0000056829.76915.2A [2]Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1...
[1]Armstrong K, Weiner J, Weber B, Asch DA. Early adoption of BRCA1/2 testing: who and why. Genet Med. 2003;5(2):92-98. doi:10.1097/01.GIM.0000056829.76915.2A [2]Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1...
9 ⅐ No. 11 Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer Kathryn J. Schlich-Bakker, MSc1, Herman F. J. ten Kroode, PhD1, Carla C. Wa´rla´m-Rodenhuis, MD2, Jan van den Bout, PhD3, and Margreet G. E. M. Aus...
另外,Nature还同期配发了题为《Thousands of short cuts to genetic testing》的评述文章,积极评述了这篇文章,并称这项工作让研究人员意识到精准医学的前景。 中国抗癌协会乳腺癌专业委员会发布的《中国抗癌协会乳腺癌诊治指南与规范》中,明确推荐乳腺癌高危人群进行遗传性BRCA1/2基因检测。阅微基因遗传性乳腺癌/卵巢...
Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.